Interpreting a Diagnosis of Atypical Squamous Cells of Undetermined Significance in Cervical Cytology and its Association with Human Papillomavirus

A retrospective analysis of 180 cases in Kuwait

**Abstract:** Atypical squamous cells of undetermined significance (ASC-US) represent a diagnostic challenge during cervical cytology. This study aimed to review and identify high-risk human papillomavirus (HR-HPV) genotypes among previously diagnosed ASC-US cases in Kuwait. **Methods:** This retrospective study analysed 180 cases diagnosed as ASC-US between June 2017 and May 2018 at the Mubarak Al-Kabeer Hospital, Kuwait. Cervical specimens were assayed to determine the presence of HR-HPV DNA; subsequently, positive cases underwent genotyping and were categorised into three groups (HPV 16, HPV 18/45 and other HR-HPV types). **Results:** In total, ASC-US was confirmed in only 105 cases (58.3%), with the remaining cases reclassified as negative for intraepithelial lesions or malignancy (NILM; 32.2%) and epithelial cell abnormalities (ECA; 9.4%). Of these, 62 Kuwaiti women had confirmed ASC-US between June 2017 and May 2018: 20 ASC-US cases contained HPV 16 (n = 1), both HPV 16 and 18/45 (n = 1) and other HR-HPV genotypes, respectively. Of those with HR-HPV DNA, the NILM case had the HPV 18/45 genotype, while the six ECA cases had the HPV 16 (n = 1), both HPV 16 and 18/45 (n = 1) and other HR-HPV (n = 4) genotypes. **Conclusion:** Overall, HR-HPV DNA was present in 19% of ASC-US cases compared to 1.7% of NILM cases initially misdiagnosed as ASC-US. Re-review of cervical cytology diagnoses may reduce unnecessary costs associated with HR-HPV genotyping.

**Keywords:** Cervical Smears; Atypical Squamous Cells of Undetermined Significance; Human Papilloma Virus; Cytological Techniques; Papanicolaou Test; Kuwait.
The presence of atypical squamous cells on cervical smears represents a diagnostic challenge for both pathologists and clinicians. According to the revised Bethesda classification system, cervical epithelial abnormalities are categorised as either atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells without ruling out a high-grade lesion (ASC-H), low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL) or squamous cell carcinomas. Under this system, a diagnosis of ASC-US is issued when the cervical epithelial cells demonstrate cytological changes suggestive of a squamous intraepithelial lesion, but without definitive qualitative or quantitative confirmation. Despite the existence of these diagnostic criteria, accurate identification of ASC-US cases remains difficult, thus resulting in high rates of misdiagnosis and overinterpretation during cervical cytology screening.

In humans, the vast majority of cases of cervical cancer are linked to human papillomavirus (HPV) infections. As such, HPV testing is highly recommended for patients diagnosed with ASC-US in order to determine whether further follow-up, in the form of an urgent colposcopy, is necessary. There are over 100 different HPV genotypes, of which approximately 40 are known to infect the genital tract; of these, 18 are believed to play a significant role in the pathogenesis of cervical cancers, most commonly types 16, 18 and 45. These variants are therefore categorised as high-risk HPV (HR-HPV) genotypes.

Few studies have sought to assess the spectrum of HR-HPV genotypes among women in Gulf Cooperation Council (GCC) countries, which differ significantly from those reported elsewhere in the world likely as a result of racial diversity. For instance, previous research indicates that HR-HPV genotypes in Kuwait mostly consist of types other than 16, 18 and 45. Similarly, Ali et al. showed that HR-HPV types other than 16 and 18 were most prevalent in GCC countries. This study aimed to review previously diagnosed ASC-US cases at a hospital in Kuwait to determine the rate of overinterpretation as well as to identify the prevalence of specific HR-HPV genotypes among Kuwaiti and non-Kuwaiti women.

### Methods

This retrospective study reviewed 180 cases diagnosed as ASC-US between June 2017 and May 2018 at the Mubarak Al-Kabeer Hospital, Kuwait. Cytological data from ThinPrep cervical smears (Hologic Corp., Bedford, Massachusetts, USA) were retrieved from the files of the cytology laboratory. Each case underwent blinded peer-review by two pathologists and one senior cytotechnician to confirm or correct the initial ASC-US diagnosis. Cases were classified using the 2014 revised Bethesda system as either negative for intraepithelial lesions or malignancy (NILM), ASC-US, atypical glandular cells (AGC), LSILs or HSILs.

Subsequently, the cervical samples were assayed to determine the presence of HR-HPV DNA. The assay technique was conducted using the Panther system of the Aptima HPV Assay (Hologic Corp.). Samples from the ThinPrep vials were transferred to the Aptima transfer tube in order to capture, amplify, detect and report specific HR-HPV E6/E7 messenger ribonucleic acid transcripts. Cases were then categorised as either HR-HPV-positive (relative light unit/cut-off [RLU/CO] of ≥0.5) or HR-HPV-negative (RLU/CO of <0.5). Subsequently, the Aptima HPV 16 18/45 Genotype Assay (Hologic Corp.) was used to detect HR-HPV 16 and 18/45 genotypes in HR-HPV-positive cases.

Based on the results of the assay, HR-HPV-positive cases were subdivided into the following categories: (1) positive for HPV 16; (2) positive for HPV 18/45; (3) positive for both HPV 16 and 18/45; or (4) negative for both HPV 16 and 18/45. For the latter category, the absence of both HPV 16 and 18/45 genotypes was considered to imply the presence of other HR-HPV genotypes, given the HR-HPV-positive findings observed during the initial assay. For
Interpreting a Diagnosis of Atypical Squamous Cells of Undetermined Significance in Cervical Cytology and its Association with Human Papillomavirus

A retrospective analysis of 180 cases in Kuwait

The purposes of statistical analysis, the results of HR-HPV testing were correlated with both the corrected cytological diagnosis (i.e. NILM, ASC-US, AGC, LSIL or HSIL) and nationality (i.e. Kuwaiti or non-Kuwaiti).

This study was conducted in accordance with the Combined Ethics Committee of the Kuwaiti Ministry of Health and the Faculty of Medicine of the Health Science Centre, University of Kuwait. The procedures of the study conformed to the ethical guidelines outlined in the revised Declaration of Helsinki. Informed verbal consent was obtained from all patients.

Results

Of the 180 previously diagnosed ASC-US cases, the original diagnosis was confirmed retrospectively by peer-review in only 105 cases (58.3%). The remaining cases were reclassified as either NILM (n = 58; 32.2%) or epithelial cell abnormalities (ECA; n = 17; 9.4%), with the latter comprising seven AGC (3.9%), six LSIL (3.3%), two HSIL (1.1%) and two ASC-US with AGC (1.1%). Among the 58 NILM cases, only one (1.7%) was HR-HPV-positive; in contrast, HR-HPV DNA was present in 20 ASC-US (19%) and six ECA (35.3%) cases. Overall, the HPV 16, HPV 18/45 and both HPV 16 and 18/45 genotypes were present in five (2.8%), one (0.6%) and eight (4.4%) cases, respectively.

The remaining 13 cases (7.2%) were negative for both HPV 16 and 18/45, indicating the presence of HR-HPV variants other than types 16 and 18/45 in these specimens. Only one of the NILM cases (1.7%) and two of the ECA cases (11.8%) demonstrated the common HR-HPV genotypes 16 or 18/45 [Table 1].

| Table 1: Reclassification of and prevalence of human papillomavirus genotypes among cervical cytology cases previously diagnosed as atypical squamous cells of undetermined significance (N = 180) |
|---|
| **Reclassification** | **HPV status, n (%)** |
| | Total | Negative | Type 16 | Type 18/45 | Types 16 and 18/45 | Other | Unknown* |
| NILM | 58 (32.2) | 56 (96.6) | 0 (0) | 1 (1.7) | 0 (0) | 0 (0) | 1 (1.7) |
| ASC-US | 105 (58.3) | 84 (80) | 4 (3.8) | 0 (0) | 7 (6.7) | 9 (8.6) | 1 (1) |
| AGC | 7 (3.9) | 7 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| ASC-US and AGC | 2 (1.1) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| LSIL | 6 (3.3) | 2 (33.3) | 1 (16.7) | 0 (0) | 1 (16.7) | 2 (33.3) | 0 (0) |
| HSIL | 2 (1.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) |
| Total | 180 (100) | 151 (83.9) | 5 (2.8) | 1 (0.6) | 8 (4.4) | 13 (7.2) | 2 (1.1) |

*HPV = human papillomavirus; NILM = negative for intraepithelial lesions or malignancy; ASC-US = atypical squamous cells of undetermined significance; AGC = atypical glandular cells; LSIL = low-grade squamous intraepithelial lesions; HSIL = high-grade squamous intraepithelial lesions.

| Table 2: Reclassification of and prevalence of human papillomavirus genotypes among cervical cytology cases previously diagnosed as atypical squamous cells of undetermined significance in the Kuwaiti group (N = 104) |
|---|
| **Reclassification** | **HPV status, n (%)** |
| | Total | Negative | Type 16 | Type 18/45 | Types 16 and 18/45 | Other | Unknown* |
| NILM | 36 (34.6) | 34 (94.4) | 0 (0) | 1 (2.8) | 0 (0) | 0 (0) | 1 (2.8) |
| ASC-US | 62 (59.6) | 49 (79) | 3 (4.8) | 0 (0) | 6 (9.7) | 4 (6.5) | 0 (0) |
| AGC | 2 (1.9) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| ASC-US and AGC | 2 (1.9) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| LSIL | 2 (1.9) | 0 (0) | 1 (50) | 0 (0) | 0 (0) | 1 (50) | 0 (0) |
| HSIL | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Total | 104 (100) | 87 (83.7) | 4 (3.8) | 1 (1) | 6 (5.8) | 5 (4.8) | 1 (1) |

*HPV = human papillomavirus; NILM = negative for intraepithelial lesions or malignancy; ASC-US = atypical squamous cells of undetermined significance; AGC = atypical glandular cells; LSIL = low-grade squamous intraepithelial lesions; HSIL = high-grade squamous intraepithelial lesions.

*Testing not performed.
In terms of nationality, the specimens originated from 104 Kuwaiti women and 76 women of other nationalities. In the Kuwaiti group, 16 cases (15.4%) were HR-HPV-positive; of these, the HPV 16 genotype was present in four (25%) cases, HPV 18/45 in one (6.3%) and both HPV 16 and 18/45 in six (37.5%). However, five cases (31.3%) were negative for both HPV 16 and 18/45, indicating the presence of other HR-HPV variants [Table 2]. In the non-Kuwaiti group, 11 cases (14.5%) were HR-HPV positive. These included one case (9.1%) with the HPV 16 genotype and two (18.2%) with both HPV 16 and 18/45. Other HR-HPV genotypes were assumed in the remaining eight cases (72.7%) [Table 3].

The diagnosis of ASC-US was confirmed in 62 Kuwaiti and 43 non-Kuwaiti cases. Of these, HR-HPV DNA was present in 13 (21%) and seven (16.3%) cases, respectively. In the Kuwaiti ASC-US group, genotyping for the HPV 16, both HPV 16 and 18/45 and other HR-HPV variants was positive in three (4.8%), six (9.7%) and four (6.5%) cases, respectively. In contrast, genotyping for these types was positive in one (2.3%), one (2.3%) and five (11.6%) cases, respectively, in the non-Kuwaiti ASC-US group [Table 4].

**Discussion**

The diagnosis of ASC-US depends not only on the identification of well-defined cytological patterns, but also on other more subjective criteria; consequently, reproducibility of the diagnosis upon re-review can vary from 50–67.9%. Various studies have shown that a number of factors are related to the overinterpretation of atypical squamous cells including reactive changes due to reproductive tract infections associated with *Trichomonas vaginalis*, *Candida* species and bacterial vaginosis, as well as the presence of intermediate squamous cells with bland nuclear enlargement without chromatin and nuclear abnormalities. Moreover, ASC-US diagnoses are reported more frequently in women who are pregnant, lactating and postmenopausal due to the excessive glycogenation of intermediate squamous cells caused by hormones. In addition, the presence of immature metaplastic cells, suboptimal fixation, drying artifacts and other age-related changes such as degeneration due to atrophic vaginitis may be mistaken for ASC-US.

---

**Table 3:** Reclassification of and prevalence of human papillomavirus genotypes among cervical cytology cases previously diagnosed as atypical squamous cells of undetermined significance in the non-Kuwaiti group (N = 76)

| Reclassification | HPV status, n (%) |
|------------------|-------------------|
|                  | Total | Negative | Type 16 | Type 18/45 | Types 16 and 18/45 | Other | Unknown* |
| NILM             | 22 (28.9) | 22 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| ASC-US           | 43 (56.6) | 35 (81.4) | 1 (2.3) | 0 (0) | 1 (2.3) | 5 (11.6) | 1 (2.3) |
| AGC              | 5 (6.6) | 5 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| ASC-US and AGC   | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| LSIL             | 4 (5.3) | 2 (50) | 0 (0) | 0 (0) | 1 (25) | 1 (25) | 0 (0) |
| HSIL             | 2 (2.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) |
| Total            | 76 (100) | 64 (84.2) | 1 (1.3) | 0 (0) | 2 (2.6) | 8 (10.5) | 1 (1.3) |

HPV = human papillomavirus; NILM = negative for intraepithelial lesions or malignancy; ASC-US = atypical squamous cells of undetermined significance; AGC = atypical glandular cells; LSIL = low-grade squamous intraepithelial lesions; HSIL = high-grade squamous intraepithelial lesions.

*Testing not performed.

**Table 4:** Distribution of human papillomavirus genotypes according to nationality among cases with confirmed diagnoses of atypical squamous cells of undetermined significance (N = 105)

| Nationality | HPV status, n (%) |
|-------------|-------------------|
|              | Total | Negative | Type 16 | Type 18/45 | Types 16 and 18/45 | Other | Unknown* |
| Kuwaiti      | 62 (59) | 49 (79) | 3 (4.8) | 0 (0) | 6 (9.7) | 4 (6.5) | 0 (0) |
| Non-Kuwaiti  | 43 (41) | 35 (81.4) | 1 (2.3) | 0 (0) | 1 (2.3) | 5 (11.6) | 1 (2.3) |
| Total        | 105 (100) | 84 (80) | 4 (3.8) | 0 (0) | 7 (6.7) | 9 (8.6) | 1 (1) |

HPV = human papillomavirus. *Testing not performed.
Interpreting a Diagnosis of Atypical Squamous Cells of Undetermined Significance in Cervical Cytology and its Association with Human Papillomavirus

A retrospective analysis of 180 cases in Kuwait

In the current study, all cases previously diagnosed as ASC-US at a Kuwaiti hospital over a one-year period were reviewed retrospectively by three cytologists. Overall, only 58.3% of cases received confirmation of the ASC-US diagnosis, while the remaining cases were reclassified as either NILM (32.2%) or ECA (9.4%). This rate of reproducibility was comparable to that reported in previous research. The absence of well-defined cytological criteria, subjectivity of the diagnosis and various other factors may account for the overrepresentation of ASC-US diagnoses in routine reporting. In general, accurate identification of ASC-US remains a diagnostic dilemma for cytopathologists. Consequently, HPV genotyping is often incorporated to enhance cervical screening. However, this can represent a needless expense due to the high rate of false-positive diagnoses. The authors therefore recommend that ASC-US diagnoses be peer-reviewed prior to reporting in order to decrease costs associated with unnecessary HPV genotyping.

In general, the detection of HR-HPV genotypes is a useful tool to supplement abnormal cytological results. Among patients with ASC-US, the presence of an HR-HPV-positive genotype increases the likelihood of cervical intraepithelial neoplasia (CIN) grades II or III, a precursor to cervical cancer; in contrast, a negative HR-HPV test excludes high-grade CIN. As a result, HR-HPV genotyping is usually recommended for patients with ASC-US. However, the American Society for Colposcopy and Cervical Pathology does not recommend HPV testing be performed for women aged 21–29 years, instead encouraging such individuals to undergo cervical screening only every three years. For women aged 30–65 years, both cytological screening and HPV testing is recommended every five years; alternatively, screening with cytology alone can be performed every three years. In addition, HPV testing is recommended for women with LSIL and as a post-colposcopy follow-up measure for those with abnormal cytology. Cases found to be positive for HR-HPV should undergo a colposcopic examination, while those classified as NILM should return for repeated cervical cytology screening within six months.

In the current study, the most common HR-HPV types among HR-HPV-positive patients with confirmed ASC-US were HPV types other than 16 and 18/45 (45%). Few studies have been performed to determine the most prevalent HR-HPV genotypes in the GCC region. Ali et al. found that types other than HPV 16/18 were the most common genotypes among women residing in Saudi Arabia, Qatar, the United Arab Emirates and Bahrain, followed by type HPV 16. Similarly, Mallik et al. reported that the most prevalent HR-HPV genotypes in Kuwait were those other than types 16, 18 and 45. However, Al-Awadhi et al. reported contradictory findings indicating that HPV type 16 was most frequent in a cohort of women in Kuwait. In the present study, the most common HR-HPV genotypes among HR-HPV-positive Kuwaiti women regardless of cytological diagnosis were both HPV 16 and 18/45 (37.5%), followed by HR-HPV types other than 16 and 18/45 (31.3%), HPV 16 (25%) and HPV 18/45 (6.3%). Among HR-HPV-positive non-Kuwaiti women, the most prevalent genotypes were HR-HPV types other than 16 and 18/45 (72.7%), both HPV 16 and 18/45 (18.2%) and HPV 16 (9.1%).

Conclusion

The rate of overrepresentation of ASC-US cases at a Kuwaiti hospital over a one-year period was moderately high. In addition, HR-HPV DNA was present in 19% of confirmed ASC-US cases compared to only 1.7% of NILM cases initially misdiagnosed as ASC-US. Therefore, the authors strongly recommend that cytological diagnoses of ASC-US be peer-reviewed for diagnostic confirmation before undergoing HR-HPV genotyping. Careful review of cellular changes by multiple cytologists will increase the diagnostic accuracy of cytology screening, thereby reducing the patient’s anxiety as well as the cost of unnecessary HPV genotyping for false-positive cases.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

FUNDING

No funding was received for this study.

References

1. Barcelos AC, Michelin MA, Adad SJ, Murta EF. Atypical squamous cells of undetermined significance: Bethesda classification and association with human papillomavirus. Infect Dis Obstet Gynecol 2011; 2011:904674. https://doi.org/10.1155/2011/904674.
2. Nayyar R, Wilbur DC, Eds. The Bethesda System for Reporting Cervical Cytology: Definitions, criteria and explanatory notes, 3rd ed. New York, USA: Springer; 2015.
3. Nascimento AF, Cibas ES. The ASC/SIL ratio for cytopathologists as a quality control measure: A follow-up study. Am J Clin Pathol 2007; 128:633–6. https://doi.org/10.1309/aptvnplp40n00cu.
4. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244–65. https://doi.org/10.1136/jcp.55.4.244.
5. Johnston EI, Logani S. Cytologic diagnosis of atypical squamous cells of undetermined significance in perimenopausal and postmenopausal women: Lessons learned from human papillomavirus DNA testing. Cancer 2007; 111:160–5. https://doi.org/10.1002/cncr.22687.

6. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003; 16:1–17. https://doi.org/10.1128/cmrr.16.1.1-17.2003.

7. Ali MAM, Bedair RN, Abd El Atti RM. Cervical high-risk human papillomavirus infection among women residing in the Gulf Cooperation Council countries: Prevalence, type-specific distribution and correlation with cervical cytology. Cancer Cytopathol 2019; 127:567–77. https://doi.org/10.1002/cncy.22165.

8. Mallik MK, Alramadhan B, Dashti H, Al-Shaheen A, Al Juwaiser A, Das DK, et al. Human papillomaviruses other than 16, 18 and 45 are the major high risk HPV genotypes amongst women with abnormal cervical smear cytology residing in Kuwait: Implications for future vaccination strategies. Diagn Cytopathol 2018; 46:1036–9. https://doi.org/10.1002/dc.24035.

9. Krishnan K, Thomas A. Correlation of cervical cytology with high-risk HPV molecular diagnosis, genotypes, and histopathology–A four year study from the UAE. Diagn Cytopathol 2016; 44:91–7. https://doi.org/10.1002/dc.23391.

10. Al-Awadhi R, Chehadeh W, Al-Issaf W, Al-Harmi J, Al-Saleh E, Kapila K. Viral load of human papillomavirus in women with normal and abnormal cervical cytology in Kuwait. J Infect Dev Ctries 2013; 15:130–6. https://doi.org/10.3855/jidc.2748.

11. Al-Awadhi R, Chehadeh W, Jaragh M, Al-Shaheen A, Sharma P, Kapila K. Distribution of human papillomavirus among women with abnormal cervical cytology in Kuwait. Diagn Cytopathol 2013; 41:107–14. https://doi.org/10.1002/dc.21778.

12. Cox JT. Management of women with cervical cytology interpreted as ASC-US or as ASC-H. Clin Obstet Gynecol 2005; 48:160–77. https://doi.org/10.1097/01.gyn.0000151571.91814.f3.

13. Gupta S, Sodhani P. Reducing “atypical squamous cells” over-diagnosis on cervicovaginal smears by diligent cytology screening. Diagn Cytopathol 2012; 40:764–9. https://doi.org/10.1002/dc.21621.

14. Tewari R, Chaudhary A. Atypical squamous cells of undetermined significance: A follow up study. Med J Armed Forces India 2010; 66:225–7. https://doi.org/10.1016/S0377-1237(10)80042-5.

15. Yamamoto LS, Alves VA, Maeda MY, Longatto-Filho A, Utagawa ML, Eluf Neto J. A morphological protocol and guide-line on uterine cervix cytology associated to papillomavirus infection. Rev Inst Med Trop Sao Paulo 2004; 46:189–93. https://doi.org/10.1590/s0036-46652004000400003.

16. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62:147–172. https://doi.org/10.3322/caac.21139.

17. Youens KE, Hosler GA, Washington PJ, Jenevein EP, Murphy KM. Clinical experience with the Cervista HPV HR assay: Correlation of cytology and HPV status from 56,501 specimens. J Mol Diagn 2011; 13:160–6. https://doi.org/10.1016/j.jmoldx.2010.11.016.

18. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007; 11:201–22. https://doi.org/10.1097/LGT.0b013e3181585870.